Evidence map›Paper›PMID 34234356›Full record

ArticlePloS one2021

Cholangiocyte Epithelial to Mesenchymal Transition (EMT) is a potential molecular mechanism driving ischemic cholangiopathy in liver transplantation.

Niluka Wickramaratne, Ru Li, Tao Tian, Jad Khoraki, Hae Sung Kang, Courtney Chmielewski, Jerry Maitland, Loren K Liebrecht, Ria Fyffe-Freil, Susanne Lyra Lindell and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Modeling ischemic-type biliary lesionFrontiers in bioengineering and biotechnology · 2026
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Niluka WickramaratneDepartment of Surgery, School of Medicine, Virginia Commonwealth University, Richmond, VA, United States of America.
Ru LiDepartment of Surgery, School of Medicine, Virginia Commonwealth University, Richmond, VA, United States of America.
Tao TianDepartment of Surgery, School of Medicine, Virginia Commonwealth University, Richmond, VA, United States of America.
Jad KhorakiDepartment of Surgery, School of Medicine, Virginia Commonwealth University, Richmond, VA, United States of America.
Hae Sung KangDepartment of Surgery, School of Medicine, Virginia Commonwealth University, Richmond, VA, United States of America.
Courtney ChmielewskiDepartment of Physiology and Biophysics, School of Medicine, Virginia Commonwealth University, Richmond, VA, United States of America.
Jerry MaitlandDepartment of Pharmacology and Toxicology, School of Medicine, Virginia Commonwealth University, Richmond, VA, United States of America.
Loren K LiebrechtDepartment of Surgery, School of Medicine, Virginia Commonwealth University, Richmond, VA, United States of America.
Ria Fyffe-FreilDepartment of Physiology and Biophysics, School of Medicine, Virginia Commonwealth University, Richmond, VA, United States of America.
Susanne Lyra LindellDepartment of Surgery, School of Medicine, Virginia Commonwealth University, Richmond, VA, United States of America.
Martin J ManginoDepartment of Surgery, School of Medicine, Virginia Commonwealth University, Richmond, VA, United States of America.ORCID 0000-0003-2440-1952
Virginia Commonwealth University · US

Funding

The Cytoskeletal System in Preservation InjuryR01DK087737 · NIDDK · VIRGINIA COMMONWEALTH UNIVERSITY · PI MANGINO, MARTIN J. · 2010 to 2013
$1.3M
NIDDK NIH HHS R01 DK087737
6 · The paper itself

Abstract

Donation after circulatory death (DCD) has expanded the donor pool for liver transplantation. However, ischemic cholangiopathy (IC) after DCD liver transplantation causes inferior outcomes. The molecular mechanisms of IC are currently unknown but may depend on ischemia-induced genetic reprograming of the biliary epithelium to mesenchymal-like cells. The main objective of this study was to determine if cholangiocytes undergo epithelial to mesenchymal transition (EMT) after exposure to DCD conditions and if this causally contributes to the phenotype of IC. Human cholangiocyte cultures were exposed to periods of warm and cold ischemia to mimic DCD liver donation. EMT was tested by assays of cell migration, cell morphology, and differential gene expression. Transplantation of syngeneic rat livers recovered under DCD conditions were evaluated for EMT changes by immunohistochemistry. Human cholangiocytes exposed to DCD conditions displayed migratory behavior and gene expression patterns consistent with EMT. E-cadherin and CK-7 expressions fell while N-cadherin, vimentin, TGFβ, and SNAIL rose, starting 24 hours and peaking 1-3 weeks after exposure. Cholangiocyte morphology changed from cuboidal (epithelial) before to spindle shaped (mesenchymal) a week after ischemia. These changes were blocked by pretreating cells with the Transforming Growth Factor beta (TGFβ) receptor antagonist Galunisertib (1 μM). Finally, rats with liver isografts cold stored for 20 hours in UW solution and exposed to warm ischemia (30 minutes) at recovery had elevated plasma bilirubin 1 week after transplantation and the liver tissue showed immunohistochemical evidence of early cholangiocyte EMT. Our findings show EMT occurs after exposure of human cholangiocytes to DCD conditions, which may be initiated by upstream signaling from autocrine derived TGFβ to cause mesenchymal specific morphological and migratory changes.

Indexed as

Cell MovementEpithelial-Mesenchymal TransitionLiver TransplantationAnimalsBile Duct DiseasesBile DuctsCells, CulturedEpithelial CellsHumansIschemiaLiverMaleRats

Identifiers

PMID34234356
PMCPMC8263302
OpenAlexW3178139368

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.